// App-Quantinova.ai

5578 : A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Platinum Resistant Ovarian Cancer.

Researchers

Presenter

  • Agustin A. Garcia

Principal Investigators

  • John L. Hays

  • Gregory Michael Cote

  • Carlos Becerra

  • Adrian Langleben

  • Susie K Lau

  • Lynda D. Roman

  • Colleen Catherine McCormick

  • Donald A. Richards

  • Fadi S. Braiteh

  • Habte Aragaw Yimer

  • Stephen Lane Richey

  • William Jeffery Edenfield

  • Kimiko Kossler

  • Stephanie Hume

  • Youzhi Li

  • Matthew Hitron

  • Chiang Li

Medical Centers

  • Los Angeles County Hospital/ University of Southern California, Los Angeles, CA

  • Ohio State University Wexner Medical Center, Columbus, OH

  • Massachusetts General Hospital, Boston, MA

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • St. Mary's Hospital, Westmount, QC, Canada

  • Montreal University, Montreal, QC, Canada

  • Los Angeles County Hospital/ University of Southern California, Los Angeles, CA

  • The John Hopkins Hospital, Portland, OR

  • Tyler Cancer Center, US Oncology Research, McKesson Specialty Health, Houston, TX

  • The US Oncology Network/McKesson Specialty Health, The Woodlands, TX

  • Texas Oncology, Tyler, TX

  • Texas Oncology, The US Oncology Network, McKesson Specialty Health, Fort Worth, TX

  • Institute for Translational Oncology Research, Greenville Hospital System/University Medical Center, Greenville, SC

  • Boston Biomedical Inc., Cambridge, MA

Locations

  • United States

  • Canada

Companies

  • Boston Biomedical, I

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Peritoneal cancer

  • Gynaecological cancer

Biomarkers

  • N/A

Drug/Treatment

  • Napabucasin

  • Paclitaxel

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01325441

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved